Interview: Judith Greciet – CEO, Onxeo, France
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Resulting from the merger of BioAlliance Pharma (France) and Topotarget (Denmark) in July 2014, Onxeo is a new leader in European biotechnology. Thanks to a unique portfolio of advanced stage products and dedicated teams of experts, Onxeo aims to take a leading position in the field of orphan oncology drugs. Through bringing pioneering drugs to market, the company wants to improve patients’ lives, fund continuous investment in R&D of orphan diseases, and create value for all company’s stakeholders and shareholders. It has three strategic programs in advanced development and two products already registered in the European and US markets, demonstrating its teams’ expertise and know-how.
49 boulevard du Général Martial Valin
75015 PARIS, France
Tel: +33 (0)1 45 58 76 00
Fax: +33 (0)1 45 58 08 81
Investors: investors@onxeo.com
Email: contact@onxeo.com
Website: www.onxeo.com
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Joël Jaouen, president of France Alzheimer, provides important insights into the role and objectives of the patient association. He explains why France Alzheimer together with other learned societies filed a…
PharmaBoardroom’s list of personalities whose voices, opinions and decisions matter in French pharma’s industry, regulatory affairs, reimbursement and pricing. Maurice-Pierre Planel — President of CEPS Maurice-Pierre Planel Has been…
Lundbeck France and Benelux’s Lourdes Pla discusses Europe-wide restructuring, the importance of the French affiliate to the global group and the government’s attitude towards healthcare and neuroscience. We are…
Gérard Raymond, president of the Fédération Francaise des Diabétiques (FFD – French Diabetes Federation), gives an update on the situation of diabetes in France and explains the challenges for patient…
Christophe Cizeron, president of Lyonbiopole, discusses the important economic and industrial position of the research cluster in the Rhone-Alps Region as well as the challenges posed by domestic and international…
Vincent Leonhardt explains how the French administration’s zeal for life science innovation can actually place pressure on some pharma SMEs. He also discusses the challenges he faced during his first…
Pierre Moustial, CEO of URGO Group, explains the life-changing advancement in wound care treatments that URGO has been providing to patients all over the world as well as his upcoming…
Thomas Courbe, general director of the DGE (Direction Générale des Entreprises – General Directorate for Enterprises), speaks about the role of the DGE and the implementation of new policies oriented…
Stéphane Roques, CEO of Medicen, the health care cluster for the Paris region, discusses his vision for Medicen and the changes he has made during his first few months in…
Pierre Moustial, chairman of MedTech in France, the association of medical technology companies in France, discusses the challenges for French healthcare start-ups to scale-up and explains why France has no…
Frédérique Vidal, the French Minister of Higher Education, Research and Innovation, discusses her plans to create innovation campuses to facilitate the collaboration between industry, institutes and academia. She also highlights…
Cancer is the leading cause of death in France, accounting for 28.5% of all deaths in 2014, followed by cardiovascular diseases, which accounted for 25%. However, there are gender differences:…
See our Cookie Privacy Policy Here
